FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Stack-Bibliothek

Aggressive Cut Stack

Fat Lossadvanced
31
Share
Peptide

3

Durchschnittliche tägliche mcg

2,571

Niveau

advanced

Hinzugefügt

May 16, 2026

Übersicht

The Aggressive Cut Stack is a high-potency fat loss protocol designed for experienced peptide users seeking rapid and sustained body recomposition. This advanced stack combines three powerful compounds that target adipose tissue through complementary metabolic pathways, creating a synergistic effect far greater than any single agent alone. Semaglutide, a GLP-1 receptor agonist administered at 500mcg weekly, dramatically reduces appetite and improves insulin sensitivity by mimicking the incretin hormone system. It slows gastric emptying and acts on hypothalamic hunger centers, making caloric restriction feel effortless rather than punishing. Research published in the New England Journal of Medicine has demonstrated significant reductions in body weight with sustained GLP-1 agonist therapy. Tesamorelin at 2000mcg daily specifically targets visceral adipose tissue—the metabolically dangerous fat surrounding internal organs. Originally developed for HIV-associated lipodystrophy, tesamorelin stimulates growth hormone releasing hormone (GHRH) receptors, promoting lipolysis while preserving lean muscle mass. Clinical trials have shown meaningful reductions in trunk fat without the side effects associated with exogenous GH administration. AOD-9604, dosed at 500mcg daily, is a modified fragment of human growth hormone (amino acids 177-191) that stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or growth. It activates beta-3 adrenergic receptors in fat tissue, accelerating fatty acid oxidation. Protocol Notes: Semaglutide should be titrated slowly over 4-6 weeks to minimize gastrointestinal side effects. Tesamorelin and AOD-9604 are best administered on an empty stomach, ideally in the morning before food. This stack is suited for individuals who have already optimized diet and training, have prior peptide experience, and are looking to break through stubborn fat loss plateaus. Cycle duration is typically 12-16 weeks with bloodwork monitoring recommended at baseline and mid-cycle.

Dosierprotokoll

500 mcg

pro Dosis

2,000 mcg

pro Dosis

500 mcg

pro Dosis

Ziele & Beweise

Beweisstufe:community

Comments

Sign in to join the discussion

Erklärung: Dieser Stack ist community-beigetragen und dient nur Forschungszwecken. Peptide Contacts überprüft die Sicherheit oder Effektivität beigetragener Stacks nicht. Bevor Sie irgendein Peptid-Protokoll einsetzen, beraten Sie sich stets mit einer qualifizierten Gesundheitskennzeichnung.